With 1.91 million shares changed hands, the volume of the stock remained lighter than its average volume of 4.0 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.8 whereas the lowest price it dropped to was $3.51. The 52-week range on CMRX shows that it touched its highest point at $3.69 and its lowest point at $0.75 during that stretch. It currently has a 1-year price target of $8.40. Beta for the stock currently stands at 0.34.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CMRX was up-trending over the past week, with a rise of 2.31%, but this was up by 306.94% over a month. Three-month performance surged to 286.38% while six-month performance rose 333.03%. The stock gained 266.88% in the past year, while it has gained 1.72% so far this year. A look at the trailing 12-month EPS for CMRX yields -0.94 with Next year EPS estimates of -1.04. For the next quarter, that number is -0.26. This implies an EPS growth rate of -6.55% for this year and -4.88% for next year.
Float and Shares Shorts:
At present, 89.94 million CMRX shares are outstanding with a float of 80.14 million shares on hand for trading. On 2024-12-13, short shares totaled 3.44 million, which was 382.0 higher than short shares on 1731628800. In addition to Mr. Michael T. Andriole M.B.A. as the firm’s CEO, President & Director, Dr. Michael A. Alrutz J.D., Ph.D. serves as its Senior VP, General Counsel & Corporate Secretary.
Institutional Ownership:
Through their ownership of 0.45648998 of CMRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, CMRX reported revenue of $26000.0 and operating income of -$24793000.0. The EBITDA in the recently reported quarter was -$24772000.0 and diluted EPS was -$0.26.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CMRX analysts setting a high price target of 11.0 and a low target of 6.0, the average target price over the next 12 months is 8.4. Based on these targets, CMRX could surge 210.73% to reach the target high and rise by 69.49% to reach the target low. Reaching the average price target will result in a growth of 137.29% from current levels.
Analysts have provided yearly estimates in a range of -$0.95092 being high and -$1.031 being low. For CMRX, this leads to a yearly average estimate of -$0.99096.
